Methotrexate in the Treatment of Psoriasis and Rheumatoid Arthritis: Mechanistic Insights, Current Issues and Novel Delivery Approaches - PubMed (original) (raw)
Review
Methotrexate in the Treatment of Psoriasis and Rheumatoid Arthritis: Mechanistic Insights, Current Issues and Novel Delivery Approaches
Panonnummal Rajitha et al. Curr Pharm Des. 2017.
Abstract
Our review is focused on the use of methotrexate in drug therapy of two autoimmune diseases, psoriasis and rheumatoid arthritis (RA). The article describes the pathogenesis of psoriasis and RA, the role of methotrexate in the treatment of these diseases with more focused review on the mechanism behind the clinical benefits of methotrexate therapy. Methotrexate due to its cytotoxic, anti-inflammatory and immune modulatory activities provides clinical benefits in the therapy of the selected diseases. This review also gives a panorama of the problems associated with the use of methotrexate in the selected diseases and the guidelines provided by FDA for its safe use. The novel colloidal drug delivery systems of methotrexate, with particular emphasis on advantages offered by liposomal formulation, niosomal gel, hydrogel, albumin conjugates, nanoparticles and nano structured lipid carriers in psoriasis and RA are also reviewed. It seemed that the use of newer colloidal carriers with improved skin permeability by minimizing its systemic availability will be a useful strategy to reduce the toxic effects of the drug in psoriatic patients. In rheumatoid arthritis patients, the development of newer therapeutic strategies using appropriate targeting ligands that specifically deliver the drug to the inflamed joint space will help to overcome its toxic effects by minimizing the systemic exposure.
Keywords: Methotrexate; colloidal carriers; hydrogel; immune modulatory activities; niosomal gel; psoriasis; rheumatoid arthritis.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Similar articles
- A hyaluronic acid-methotrexate conjugate for targeted therapy of rheumatoid arthritis.
Shin JM, Kim SH, Thambi T, You DG, Jeon J, Lee JO, Chung BY, Jo DG, Park JH. Shin JM, et al. Chem Commun (Camb). 2014 Jul 21;50(57):7632-5. doi: 10.1039/c4cc02595d. Chem Commun (Camb). 2014. PMID: 24893961 - Methotrexate Aspasomes Against Rheumatoid Arthritis: Optimized Hydrogel Loaded Liposomal Formulation with In Vivo Evaluation in Wistar Rats.
Ghosh S, Mukherjee B, Chaudhuri S, Roy T, Mukherjee A, Sengupta S. Ghosh S, et al. AAPS PharmSciTech. 2018 Apr;19(3):1320-1336. doi: 10.1208/s12249-017-0939-2. Epub 2018 Jan 16. AAPS PharmSciTech. 2018. PMID: 29340978 - Methotrexate and cardiovascular risk in rheumatic diseases:A comprehensive review.
Verhoeven F, Prati C, Chouk M, Demougeot C, Wendling D. Verhoeven F, et al. Expert Rev Clin Pharmacol. 2021 Sep;14(9):1105-1112. doi: 10.1080/17512433.2021.1932461. Epub 2021 Jun 1. Expert Rev Clin Pharmacol. 2021. PMID: 34006152 Review. - Methotrexate: a gold standard for treatment of rheumatoid arthritis.
Shinde CG, Venkatesh MP, Kumar TM, Shivakumar HG. Shinde CG, et al. J Pain Palliat Care Pharmacother. 2014 Dec;28(4):351-8. doi: 10.3109/15360288.2014.959238. Epub 2014 Oct 16. J Pain Palliat Care Pharmacother. 2014. PMID: 25322199 Review. - A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis.
Abolmaali SS, Tamaddon AM, Dinarvand R. Abolmaali SS, et al. Cancer Chemother Pharmacol. 2013 May;71(5):1115-30. doi: 10.1007/s00280-012-2062-0. Epub 2013 Jan 6. Cancer Chemother Pharmacol. 2013. PMID: 23292116 Review.
Cited by
- From Cancer to Immune-Mediated Diseases and Tolerance Induction: Lessons Learned From Immune Oncology and Classical Anti-cancer Treatment.
Klöß S, Dehmel S, Braun A, Parnham MJ, Köhl U, Schiffmann S. Klöß S, et al. Front Immunol. 2020 Jul 8;11:1423. doi: 10.3389/fimmu.2020.01423. eCollection 2020. Front Immunol. 2020. PMID: 32733473 Free PMC article. Review. - Lipophilic Prodrug of Methotrexate in the Membrane of Liposomes Promotes Their Uptake by Human Blood Phagocytes.
Tretiakova DS, Khaidukov SV, Babayants AA, Frolova IS, Shcheglovitova ON, Onishchenko NR, Vodovozova EL. Tretiakova DS, et al. Acta Naturae. 2020 Jan-Mar;12(1):99-109. doi: 10.32607/actanaturae.10946. Acta Naturae. 2020. PMID: 32477604 Free PMC article. - SLC19A1 transports immunoreactive cyclic dinucleotides.
Luteijn RD, Zaver SA, Gowen BG, Wyman SK, Garelis NE, Onia L, McWhirter SM, Katibah GE, Corn JE, Woodward JJ, Raulet DH. Luteijn RD, et al. Nature. 2019 Sep;573(7774):434-438. doi: 10.1038/s41586-019-1553-0. Epub 2019 Sep 11. Nature. 2019. PMID: 31511694 Free PMC article. - Development of biomedical hydrogels for rheumatoid arthritis treatment.
Baig MMFA, Wong LK, Zia AW, Wu H. Baig MMFA, et al. Asian J Pharm Sci. 2024 Feb;19(1):100887. doi: 10.1016/j.ajps.2024.100887. Epub 2024 Feb 5. Asian J Pharm Sci. 2024. PMID: 38419762 Free PMC article. Review. - Development of a Novel Methotrexate-Loaded Nanoemulsion for Rheumatoid Arthritis Treatment with Site-Specific Targeting Subcutaneous Delivery.
Suresh P, Salem-Bekhit MM, Veedu HP, Alshehri S, Nair SC, Bukhari SI, Viswanad V, Taha EI, Sahu RK, Ghoneim MM, Elbagory I. Suresh P, et al. Nanomaterials (Basel). 2022 Apr 11;12(8):1299. doi: 10.3390/nano12081299. Nanomaterials (Basel). 2022. PMID: 35458007 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical